Keratosis, Actinic Clinical Trial
Official title:
Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study
A multi-centre randomised controled single blind clinical phase IV trial with the aim to determine the most effective treatment in terms of lesion reduction, costs and patient satisfaction in treatment of actinic keratosis (AK), when comparing topical treatment with photodynamic therapy (PDT), 5% 5-fluorouracil (5-FU) cream, 5% Imiquimod (IMI) cream and ingenol mebutate (IM) gel.
Skin cancer is the most common cancer in Caucasians and therefore a major public health issue. Its incidence is increasing rapidly. Actinic keratosis (AK) is the most prevalent precancerous chronic skin condition. It can transform into squamous cell carcinoma (SCC). AK's generally arise in a skin area that has diffuse precancerous damage, a phenomenon called field cancerization. Because of its precancerous character, it is advised to treat AK and herewith prevent development into SCC. The most frequently used field-directed treatments in the Netherlands are photodynamic therapy (PDT), topical 5% f-fluorouracil (5% 5-FU) and topical 5% Imiquimod (5% IMI). Lately another topical product is approved by Dutch healthcare insurances: Ingenol mebutate (IM). Up to date, which treatment the patient will receive, does not rely on evidence-based-medicine, but generally on the preference of the physician. Current national and international guidelines state no clear recommendations for the best choice of therapy. The aim of this study determine which treatment is the most effective treatment in terms of lesion reduction, costs and patient satisfaction when comparing topical treatment with photodynamic therapy (PDT), 5% 5-fluorouracil (5-FU) cream, 5% Imiquimod (IMI) cream and ingenol mebutate (IM) gel, in treatment of actinic keratosis (AK). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03076892 -
Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS
|
N/A | |
| Terminated |
NCT03076918 -
Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy
|
N/A | |
| Completed |
NCT05356572 -
A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin
|
N/A | |
| Recruiting |
NCT05387525 -
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
|
Phase 4 | |
| Completed |
NCT02594644 -
The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
|
N/A | |
| Completed |
NCT01458587 -
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
|
Phase 2 | |
| Completed |
NCT05260073 -
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
|
||
| Active, not recruiting |
NCT06014697 -
OCT and Invasion in Cutaneous Skin Lesions
|
||
| Completed |
NCT05279131 -
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
|
Phase 3 | |
| Completed |
NCT05481073 -
UV Sensor in Patients With Actinic Keratosis
|
||
| Completed |
NCT03697590 -
Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
|
Phase 4 | |
| Withdrawn |
NCT02813902 -
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
|
Phase 1 | |
| Recruiting |
NCT05636800 -
Microwave Treatment for Actinic Keratosis
|
N/A | |
| Completed |
NCT02628236 -
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
|
Phase 2 | |
| Recruiting |
NCT06135415 -
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
|
Phase 3 | |
| Completed |
NCT02644187 -
Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol
|
N/A | |
| Completed |
NCT02281136 -
MUSE Study of Levulan Kerastick
|
Phase 2 | |
| Completed |
NCT05060237 -
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
|
Phase 1 | |
| Terminated |
NCT04269395 -
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
|
Phase 3 |